Heart Failure: A Deficiency of Energy-A Path Yet to Discover and Walk

Ioannis Paraskevaidis1, Christos Kourek2, Dimitrios Farmakis3

  • 16th Department of Cardiology, Hygeia Hospital, 151 23 Athens, Greece.

Biomedicines
|November 27, 2024
PubMed

Insights

Understanding heart failure requires exploring its energetic starvation model. New imaging, biomedicine, nanotechnology, and AI can reveal metabolic changes for earlier diagnosis and treatment.

Area of Science:

  • Cardiology
  • Biochemistry
  • Medical Imaging

Background:

  • Heart failure is a complex syndrome primarily understood through its phenotypic presentation.
  • The heart is the most energy-intensive organ, crucial for functions like ion exchange and excitation-contraction coupling.
  • Current understanding of heart failure pathogenesis lacks focus on the energetic starvation model.

Purpose of the Study:

  • To emphasize the importance of the energetic starvation model in understanding heart failure.
  • To explore how advancements in technology can elucidate cardiac energy metabolism.
  • To encourage further research into the metabolic underpinnings of heart failure.

Main Methods:

  • Review of current understanding of cardiac energy metabolism.
  • Discussion of novel approaches including advanced imaging, biomedicine, nanotechnology, and artificial intelligence.
  • Synthesis of existing knowledge to propose a new research direction.

Main Results:

  • Cardiac energy metabolism plays a critical role in heart failure pathophysiology.
  • Technological advancements offer unprecedented opportunities to study cardiac energetics.
  • The energetic starvation model provides a novel framework for investigating heart failure.

Conclusions:

  • A deeper understanding of cardiac energy metabolism is essential for characterizing heart failure.
  • Integrating advanced technologies can reveal crucial metabolic changes in heart disease.
  • Focusing on energetic deficiency may lead to earlier detection and more effective therapies for heart failure.

Related Concept Videos

Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386